The liver, liver metastasis and liver cancer: A special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies

Immunotherapy

Volumn 4, Issue 11, 2012, Pages 1081-1085

  Mazzolini, Guillermo ^a   Ochoa, María C ^b   Morales Kastresana, Aizea ^b   Sanmamed, Miguel F ^c   Melero, Ignacio ^b,c  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

cytokines; gene therapy; immunostimulatory monoclonal antibody; liver

Indexed keywords

CTLA 4 MONOCLONAL ANTIBODY; CYTOKINE; INTERLEUKIN 12; IPILIMUMAB; MONOCLONAL ANTIBODY; PD 1 MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; RECOMBINANT INTERLEUKIN 15; TICILIMUMAB; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTINUOUS INFUSION; CUTANEOUS MELANOMA; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE ESCALATION; DRUG FEVER; HEPATITIS B; HEPATITIS C; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; LYMPHOID ORGAN; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TH1 CELL; ULCERATIVE COLITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; GENETIC THERAPY; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-15; LIVER; LIVER NEOPLASMS; LYMPHOID TISSUE; MICE; NEOPLASM METASTASIS; PROTEIN ENGINEERING;

EID: 84870404370     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.99     Document Type: Review

References (40)

1. Crispe IN. The liver as a lymphoid organ. Annu. Rev. Immunol. 27, 147-163 (2009).
2. Gao B, Jeong WI, Tian Z. Liver: an organ with predominant innate immunity. Hepatology 47(2), 729-736 (2008).
3. Swain MG. Natural killer T cells within the liver: conductors of the hepatic immune orchestra. Dig. Dis. 28(1), 7-13 (2010).
4. Wisse E, Luo D, Vermijlen D, Kanellopoulou C, De Zanger R, Braet F. On the function of pit cells, the liver-specific natural killer cells. Semin. Liver Dis. 17(4), 265-286 (1997).
5. O'Connell PJ, Morelli AE, Logar AJ, Thomson AW. Phenotypic and functional characterization of mouse hepatic CD8 a+ lymphoid-related dendritic cells. J. Immunol. 165(2), 795-803 (2000).
6. Starzl TE, Demetris AJ, Trucco M et al. Systemic chimerism in human female recipients of male livers. Lancet 340(8824), 876-877 (1992).
7. Bishop GA, Ierino FL, Sharland AF et al. Approaching the promise of operational tolerance in clinical transplantation. Transplantation 91(10), 1065-1074 (2011).
8. Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH. Chronic inflammation, immune escape and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology doi:10.1002/hep.25674 (2012) (Epub ahead of print).
9. Matar P, Alaniz L, Rozados V et al. Immunotherapy for liver tumors: present status and future prospects. J. Biomed. Sci. 16, 30 (2009).
10. Mazzolini G, Prieto J, Melero I. Gene therapy of cancer with interleukin-12. Curr. Pharm. Des. 9(24), 1981-1991 (2003).
11. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13(2), 155-168 (2002).
12. Leonard JP, Sherman ML, Fisher GL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-g production. Blood 90(7), 2541-2548 (1997).
13. Berraondo P, Prieto J, Gonzalez-Aseguinolaza G. Advances in interleukin-12 gene therapy for acquired liver diseases. Curr. Gene Ther. 9(2), 62-71 (2009).
14. Sangro B, Mazzolini G, Ruiz J et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 22(8), 1389-1397 (2004).
15. Reboredo M, Zabala M, Mauleon I et al. Interleukin-12 inhibits liver-specific drug-inducible systems in vivo. Gene Ther. 15(4), 277-288 (2008).
16. Zabala M, Lasarte JJ, Perret C et al. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J. Hepatol. 47(6), 807-815 (2007).
17. Waldmann TA, Lugli E, Roederer M et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117(18), 4787-4795 (2011).
18. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33(1), 35-41 (2012).
19. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7(2), 95-106 (2007).
20. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 157(1), 9-19 (2009).
21. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
22. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
23. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
24. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
25. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 8, 1 (2008).
26. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin. Oncol. 37(5), 450-454 (2010).
27. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37(5), 508-516 (2010).
28. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612-1616 (2011).
29. Dubrot J, Milheiro F, Alfaro C et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol. Immunother. 59(8), 1223-1233 (2010).
30. Mazzolini G, Murillo O, Atorrasagasti C et al. Immunotherapy and immunoescape in colorectal cancer. World J. Gastroenterol. 13(44), 5822-5831 (2007).
31. Malvicini M, Ingolotti M, Piccioni F et al. Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. Mol. Oncol. 5(3), 242-255 (2011).
32. Ko HJ, Kim YJ, Kim YS et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67(15), 7477-7486 (2007).
33. Vincent J, Mignot G, Chalmin F et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052-3061 (2010).
34. Michaud M, Martins I, Sukkurwala AQ et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334(6062), 1573-1577 (2011).
35. Avella DM, Li G, Schell TD et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology 55(1), 141-152 (2012).
36. Ma L, Luo L, Qiao H et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J. Hepatol. 46(1), 98-106 (2007).
37. Huang KW, Wu HL, Lin HL et al. Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. Proc. Natl Acad. Sci. USA 107(33), 14769-14774 (2010).
38. Uno T, Takeda K, Kojima Y et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12(6), 693-698 (2006).
39. Melero I, Martinez-Forero I, Dubrot J, Suarez N, Palazon A, Chen L. Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin. Cancer Res. 15(5), 1507-1509 (2009).
40. Martinez-Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I. Workshop on immunotherapy combinations society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011. J. Transl. Med. 10(1), 108 (2012).s